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Summary
 
The crucial immunological function of the classical human major histocompatibility complex
(MHC) class I molecules, human histocompatibility leukocyte antigen (HLA)-A, -B, and -C, is
the presentation of peptides to T cells. A secondary function is the inhibition of natural killer
(NK) cells, mediated by binding of class I molecules to NK receptors. In contrast, the function
of the nonclassical human MHC class I molecules, HLA-E, -F, and -G, is still a mystery. The
specific expression of HLA-G in placental trophoblast suggests an important role for this mole-
cule in the immunological interaction between mother and child. The fetus, semiallograft by its
genotype, escapes maternal allorecognition by downregulation of HLA-A and HLA-B mole-
cules at this interface. It has been suggested that the maternal NK recognition of this downreg-
ulation is balanced by the expression of HLA-G, thus preventing damage to the placenta. Here,
we describe the partial inhibition of NK lysis of the MHC class I negative cell line LCL721.221
upon HLA-G transfection. We present three NK lines that are inhibited via the interaction of
their NKAT3 receptor with HLA-G and with HLA-Bw4 molecules. Inhibition can be blocked
by the anti-NKAT3 antibody 5.133. In conclusion, NK inhibition by HLA-G via NKAT3
may contribute to the survival of the fetal semiallograft in the mother during pregnancy.
 
I
 
n the last five years three major functions of the classical
human MHC class I molecules, HLA-A, -B, and -C have
been established: (
 
a
 
) presentation of peptides to T cells (1,
2); (
 
b
 
) inhibition of NK cells via inhibitory NK receptors,
KIR
 
1
 
 (3–6); and (
 
c
 
) activation of NK cells via activatory NK
receptors, KAR (7–9).
In contrast, the function of the nonclassical human MHC
class I molecules is only poorly understood (10). Of the 19
nonclassical MHC I genes, 3 genes, HLA-E, -F, and -G,
were found to be expressed as proteins (11). The HLA-G
gene has the same general structure as the classical MHC
class I genes with five exons and three introns. It gives rise
to five differently spliced mRNAs lacking zero, one, or
even two exons. All these mRNAs are translated; one leads
to a soluble HLA-G molecule without the transmembrane
and intracellular domains (12, 13). Both the soluble and the
largest membrane-associated HLA-G molecules assemble
trimeric complexes with 
 
b
 
2-microglobulin (
 
b
 
2m) and en-
dogeneously derived peptides that show a distinct peptide
motif similar to that of peptides bound to classical MHC
class I molecules (14, 15).
HLA-G is selectively expressed at the feto–maternal in-
terface. Extravillous cytotrophoblasts that invade maternal
tissue as well as amnionic epithelium express no HLA-A or
HLA-B molecules (16–18) but do express HLA-C mole-
cules (19). In addition, high levels of HLA-G are present
on the cell surface and at least some components, LMP7
and TAP, of the endogeneous antigen presentation path-
way are overexpressed (20, 21).
This restricted expression, as well as the potential of
HLA-G to assemble trimeric classical MHC class I–like com-
plexes, led to the hypothesis that HLA-G might play an
important role in the immunological interaction between
mother and child (22). Therefore, two hypotheses have
been put forward. One suggests that HLA-G-restricted CTL
survey the trophoblast for viral infections or malignancy
through the presented peptide pool (10). The second hy-
pothesis, which is supported by this report, proposes an in-
hibitory effect of HLA-G on those NK cells that would
normally recognize the absence of the classical MHC class I
 
1
 
Abbreviations used in this paper:
 
 KAR, killer activatory receptor; KIR,
killer inhibitory receptor; LGL, large granular lymphocyte.
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molecules and therefore would destroy the fetal cytotro-
phoblast (14, 23).
NK cells were found to detect the absence of MHC I
molecules on the cell surface and this finding led to the
missing-self hypothesis (24). Subsequently two groups of re-
ceptors were reported on NK cells: activatory and inhibitory
receptors (25). Engagement of the activatory receptors leads
to target cell killing, while stimulation of the inhibitory re-
ceptors prevents killing. In humans, the members of both
groups belong to the immunoglobulin superfamily and rec-
ognize public epitopes in MHC class I molecules. They dif-
fer mainly in the transmembrane and cytoplasmic domains,
which suggests that the recognition pattern is similar, but the
signaling different (7, 9). Until now, four human inhibitory
NK receptors and their specificities have been identified,
NKAT1–4 (3; Table 1). The expression of the inhibitory
NK receptors is tightly regulated: receptors for self-MHC
class I molecules are upregulated, while the general expres-
sion pattern for KIRs seems to be inherited (26).
To prove that NK inhibition by HLA-G is an effective
protection for the fetus, inhibition of the majority of NK
cells in the mother has to be demonstrated and the mediat-
ing receptors have to be identified. Partial inhibition of NK
cells in a CD56
 
1
 
 bulk culture has been found (27, 28), but to
date no interacting receptor could be identified. In this study,
we address the question of NK bulk culture inhibition and
show for the first time NKAT3 inhibition by HLA-G.
 
Materials and Methods
 
NK Lines and Populations.
 
PBL from healthy donors were
isolated from buffy coats by Ficoll–Hypaque density gradient cen-
trifugation using FicoLite-H (Linaris, Bettingen, Germany). The
buffy coats were obtained from the blood banks in Heidelberg
and Tübingen. To isolate NK cells, 10
 
7
 
 PBL in 80 
 
m
 
l MACS
buffer (PBS 
 
1
 
 0.5% BSA 
 
1
 
 2 mM EDTA) were incubated with
20 
 
m
 
l CD56 MicroBeads (Miltenyi Biotec GmbH, Bergisch
Gladbach, Germany) for 15 min at 6–12
 
8
 
C. CD56
 
1
 
 PBL were
separated on MiniMACS separation columns (Miltenyi Biotec)
using a VarioMACS separation magnet. Retained cells were cul-
tured in RPMI 
 
1
 
 5% human serum (HS) 
 
1
 
 1000U/ml rhIL-2
(Proleukin, Chiron GmbH, Germany) 
 
1
 
 2 mM glutamin 
 
1
 
 1 mM
sodium–pyruvate 
 
1
 
 1
 
3
 
 nonessential amino acids (Sigma Chem.
Co., St. Louis, MO) in the presence of irradiated human PBL of
any donor. NK lines were created by dilution in 96-well plates.
CD56
 
1
 
 PBL were distributed at 10, 3.3, and 1.1 cells/well. After
7 d, each well was split in three and after 7 d more, two of the
three sets of plates were used for assays against LCL721.221 and
LCL721.221.G, transfected with the full-length HLA-G locus 5.4
kb genomic DNA cells. Wells that showed high killing of
LCL721.221 and low killing of LCL721.221.G were picked from
the third set of plates and expanded.
 
Flow Cytometry.
 
10
 
6
 
 cells were labeled either with directly
FITC-labeled antibodies against CD4 (Immunotech Luminy,
France), CD8 (PharMingen, San Diego, CA), CD56 (Becton-
Dickinson, Mountain View, CA) or with primary antibodies B73.1,
 
a
 
CD16 (a gift from Dr. B. Perussia, Philadelphia, PA) and 5.133,
 
a
 
NKAT3/4, combined with a FITC-labeled goat anti–mouse
antibody (Dianova, Hamburg, Germany). For each staining, 5–10 
 
3
 
10
 
3
 
 cells were analyzed using a FACSCalibur
 
Ò
 
 flow cytometer
(Becton-Dickinson, San Jose, CA) and CellQuest software.
 
Cytolytic Assays.
 
For measurement of cytolytic activity, 
 
51
 
Cr
release assays were performed. The following cell lines were used
as targets: human HLA-null lymphoblastoid cell line LCL721.221
(29) and its HLA-G transfectant, LCL721.221.G, (27); human
MHC class I–reduced cell line C1R (30) and its HLA-B8 (pro-
vided by Dr. M. Takiguchi, Tokyo, Japan), -B
 
*
 
2705 (provided
by Dr. P. Cresswell, New Haven, CT), and -B
 
*
 
5101 (31) trans-
fectants; human STEMO cell line (32) and PHA induced blasts of
PBL of an HLA-A3
 
1
 
, -B7
 
1
 
, and -Cw7
 
1
 
 donor. PHA blasts were
obtained by culturing 10
 
6
 
 PBL with 2 
 
m
 
g PHA (Boehringer
Mannheim, Mannheim, Germany) in 1 ml 
 
a
 
MEM 
 
1
 
 5% HS 
 
1
 
2 mM glutamin for 5 d. 
 
51
 
Cr-labeled target cells were incubated
for 4 or 6 h with the NK cells in 200 
 
m
 
l RPMI 
 
1
 
 5% FCS 
 
1
 
 2
mM glutamin. Afterwards, 50 
 
m
 
l of the supernatant was harvested
and the radioactivity was measured in a microplate format scintil-
lation counter (1450 Microbeta Plus, Wallac, Turku, Finland) us-
ing solid-phase scintillation (LumaPlate-96, Packard, Groningen,
The Netherlands). Pecent-specific lysis was calculated as ([cpm
experimental well 
 
2
 
 cpm spontaneous release]/[cpm maximum
release 
 
2
 
 cpm spontaneous release]) 
 
3
 
 100%. Spontaneous re-
 
Table 1.
 
Listing of Human Inhibitory NK Receptors, their HLA Class I Counterparts, and the HLA Amino Acids Likely to be
Recognized by KIRS
 
Human inhibitory NK receptors Inhibiting HLA class I molecules Amino acids at positions
77 78 79 80
NKAT1 (46) HLA-Cw4, -Cw5, -Cw6 Asn(N) X X Lys(K)
NKAT2 (46) HLA-Cw1, -Cw3, -Cw7, -Cw8 Ser(S) X X Asn(N)
NKAT3 (46) HLA-Bw4 Ser(S) Leu(L) Arg(R) Thr(T)
Asn(N) Ile(I)
Asp(D)
NKAT4 (34, 44) HLA-A
 
*
 
0301 Asp(D) Leu(L) Gly(G) Thr(T)
NKAT3 (this report) HLA-G Asn(N) Leu(L) Gln(Q) Thr(T)
X, polymorphic position. 
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lease was determined by incubating the labeled target cells with
medium; maximum release was determined by incubating the
target cells in 1% Triton X-100 medium. The mAbs 5.133,
 
a
 
NKAT3
 
1
 
4 and HP-3E4, 
 
a
 
NKAT1 were used at a final con-
centration of 2.5 
 
m
 
g/ml.
 
Results
 
Inhibition of CD56
 
1
 
 NK Bulk Cultures by Target Cells Trans-
fected with HLA-G.
 
The effect of HLA-G transfection on
killing by CD56
 
1
 
 NK cultures was investigated using the
HLA-null human lymphoblastoid cell line LCL721.221 with
and without HLA-G transfection as targets for positively
MACS-selected CD56
 
1
 
 PBL of healthy donors. CD56
 
1
 
PBL show the phenotype of peripheral NK cells by FACS
 
Ò
 
analysis: CD16
 
1
 
, CD56
 
dim
 
, CD4
 
2
 
 and partial CD8 expres-
sion (data not shown). Our HLA-G transfectant of the
LCL721.221 cell line, LCL721.221.G, expresses the non-
classical MHC class I molecule with a mean fluorescence
value of 45–50 (14). In a 4-h 
 
51
 
Cr release assay, the specific
lysis of LCL721.221 mediated by the isolated NK popu-
lation against LCL721.221 was between 70–80% at a E/T
ratio of 1:1 (Fig. 1). At the same ratio, the killing of
LCL721.221.G was remarkably reduced (to 40–45%; Fig.
1). In both cases, the killing decreased with lower E/T ra-
tios. The CD56
 
2
 
 PBL population showed only low back-
ground killing of both cell lines (around 10% specific lysis;
Fig. 1).
 
Isolation of HLA-G-specific NK Lines.
 
Positively MACS-
selected CD56
 
1
 
 PBL from healthy donors were diluted in
96-well plates, split into three sets of plates after 7 d, and as-
sayed for killing of LCL721.221 and LCL721.221.G after
another 7 d. 50% of the NK-containing wells showed inhi-
bition of killing upon HLA-G transfection of the targets.
Seven wells that showed 50–90% higher specific lysis of
LCL721.221 compared with specific lysis of LCL721.221.G
were expanded (NKG1–7; Fig. 2). Of the seven cultures,
three cultures, NKG1, NKG2, and NKG7, preserved rec-
ognition of HLA-G in our culture conditions, and killing
of LCL721.221 by these lines was inhibited to background
levels upon HLA-G surface expression. FACS
 
Ò
 
 analysis of
the three NK lines showed homogeneous surface expres-
sion of the NK surface markers CD16 and CD56. CD4 and
CD8 expression could not be detected, as shown in Fig. 3
for NKG7. NKG1 and NKG2 showed the same phenotype
of tested surface markers: CD16
 
1
 
, CD56
 
dim
 
, CD4
 
2
 
, CD8
 
2
 
(data not shown). The ratios of specific lysis of LCL721.221
to the specific lysis of LCL721.221.G for the three lines af-
Figure 2. Lysis of CD561 PBL subcultures distributed over the wells of
a 96-well plate. Each dot represents the behavior of one well in a 51Cr re-
lease assay against LCL721.221 (y axis) and LCL721.221.G (x axis). The
marked NK lines, NKG1–7, were picked and expanded.
Figure 1. 51Cr release assay of CD561 PBL versus LCL721.221 (d), as
well as LCL721.221.G (s), and CD562 PBL versus LCL721.221(.).
Figure 3. Flow cytometry analysis of the surface molecules of NKG7
(broken line) by staining of (a) CD8 with a directly FITC-labeled aCD8
antibody; (b) CD4 with a directly FITC-labeled aCD4 antibody; (c)
CD16 with the B73.1 antibody and a FITC-labeled goat a-mouse anti-
body; (d) CD56 with a directly FITC-labeled aCD56 antibody. The neg-
ative control represents NKG7 cells incubated with the secondary goat
a-mouse antibody (solid line). 
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ter 4 wk in culture at a E/T ratio of 1:1 were the follow-
ing: NKG1, 50/18; NKG2, 35/5; NKG7, 62/21 (Fig. 4).
 
Identification of NKAT3 as the Receptor Mediating HLA-G
Inhibition.
 
This was done in two sets of experiments.
 
First, blocking of the receptor during 
 
51
 
Cr release assay
with mAbs was used to prevent inhibition by HLA-G. Sec-
ond, transfectants, as well as PHA blasts of typed donors,
were surveyed for coinhibition of NKG1, NKG2, and
NKG7. The mAbs 5.133, recognizing NKAT3 as well as
NKAT4, and HP-3E4, recognizing NKAT1, were used at
a final concentration of 2.5 
 
m
 
g/ml in the medium during
 
51Cr release assay. Addition of 5.133 prevented inhibition
of LCL721.221 lysis by HLA-G, while addition of HP-3E4
did not. This effect was observed with all three NK lines.
Representative data for NKG7 are given in Fig. 5 a. 5.133
Fab fragments and HP-3E4 antibodies were previously
used to restore NK lysis by blocking KIRs (33, 34). In
agreement with this finding, the 5.133 antibody stains the
NK lines efficiently in flow cytometry (Fig. 5 b).
To examine whether HLA-G inhibition of the NK lines is
mediated versus NKAT3 or NKAT4 reactivity of these lines,
targets expressing NKAT3 or NKAT4 ligands were tested.
Fig. 6 shows representative data obtained with the NKG7
line for recognition of (a) HLA-B*2705 or -B*5101-trans-
fected C1R cells and (b) HLA-A3-expressing cells (STEMO
and HLA-A31 PHA blasts). C1R, which is reduced in
Figure 4. 51Cr release assays of NKG1 (a), NKG2 (b), and NKG7 (c)
against LCL721.221 (d) and LCL721.221.G (s).
Figure 5. (a) 51Cr release assay of NKG7 against LCL721.221 (d) and
LCL721.221.G (s) in the presence of 2.5 mg/ml 5.133 (.) or HP-3E4
(,). (b) Flow cytometry analysis of NKAT3 and/or NKAT4 expression
of NKG7. Staining with the 5.133 antibody and a goat a–mouse FITC-
labeled secondary antibody (broken line). Staining with the secondary anti-
body only served as the negative control (solid line).
Figure 6. (a) 51Cr release assay of NKG7 against LCL721.221 (d),
LCL721.221.G (s), C1R (.), C1R-B*2705 (,), and C1R-B*5101 (j);
(b)  51Cr assay of NKG7 against LCL721.221 (d), LCL721.221.G (s),
STEMO (.), and PHA blasts of PBL of a HLA-A31, -B71 and -Cw71
donor (,).389 Münz et al.
MHC class I expression, was found to be killed by the NK
lines just as efficiently as LCL721.221 (Fig. 6 a). Only tar-
get cells expressing the HLA-B*2705/-B*5101 alleles in-
hibited the activity of the NK lines. This set of data sug-
gests that HLA-G inhibition of NKG1, NKG2, and NKG7
runs parallel to inhibition by HLA-B*2705 and -B*5101,
both of which carry the HLA-Bw4 public epitope. As shown
in Table 1, HLA-Bw4 is recognized by the NKAT3 in-
hibitory human NK receptor, while HLA-A3 reacts with
NKAT4. In conclusion, HLA-G inhibition of NKG1,
NKG2, and NKG7 can be blocked by the 5.133 antibody
that recognizes NKAT3 as well as NKAT4, but only
NKAT3 seems to mediate the inhibition of the NK lines,
because they alone can be inhibited by HLA-Bw4 but not
HLA-A*0301-bearing targets.
Discussion
In this study, we have demonstrated that half of the NK
activity of PBL can be inhibited upon HLA-G transfection
and that inhibition was mediated, in part at least, by NKAT3.
The fetus downregulates classical MHC class I molecules,
HLA-A and HLA-B, at the feto–maternal interface (22)
and, for this reason, the immune system of the mother is
not able to attack the placenta by alloreactive T cells.
However, the absence of HLA-A and HLA-B molecules
potentially renders the fetal cytotrophoblast sensitive for
NK recognition and lysis. Moreover, high numbers of
CD561 large granular lymphocytes (LGL) are present in
the decidua during early pregnancy; yet, even so, the tro-
phoblast is usually not destroyed. Up to 70% of all decidual
lymphocytes show this phenotype (35). Based on the two
NK receptor theory (25), there are two possible explana-
tions for nonrecognition of the fetal cytotrophoblast by
maternal NK cells. One is that these cells lack activatory
structures for NK cells on their surface (36) and the other
postulates a substitute for classical MHC class I molecules
inhibiting NK cells (27).
Lysis of LCL721.221 by CD561 NK cells can be re-
duced by up to 50% upon HLA-G transfection. If inhibi-
tion by HLA-G is one of the major mechanisms for pro-
tecting the fetal semiallograft from maternal NK cells, this
inhibition should be close to 100%. There are three possi-
ble explanations for the only partial inhibition of NK cells
by HLA-G in our experimental system. One reason could
be that the CD561 NK cells present in the decidua express
inhibitory NK receptors for HLA-G at higher levels, re-
sulting in stronger inhibition. It has been observed that
KIR expression on peripheral NK cells differs remarkably
between donors and often a high and a low expressing
population can be detected (25). A second explanation
could be that in addition to HLA-G, HLA-C molecules are
also expressed on first trimester trophoblast cells (19). Dif-
ferent HLA-C alleles have the potential to inhibit either
NKAT1- or NKAT2-bearing NK cells (Table 1). This ad-
ditional inhibition of NK reactivity may protect the fetus
from the remaining lysis in our model system. The third
reason could be that the expression level of HLA-G on our
LCL721.221 transfectant is lower than the physiological
HLA-G expression. Because NK cells are highly sensitive
to missing self in a density-dependent way (24), low HLA-G
levels could explain the residual lysis of our transfectant. In
the LCL721.221 cell line, TAP and LMP7 molecules are
expressed at much lower levels compared with the fetal cy-
totrophoblast cells (20, 21). Because these molecules influ-
ence the peptide supply of MHC molecules inside the ER
(37, 38) and HLA-G binds peptides as do other HLA class I
molecules (14, 15), fetal cytotrophoblast cells are expected
to express higher levels of HLA-G, which should result in a
more complete inhibition of NK cells (39). In line with this
explanation is the finding that externally added peptide up-
regulates HLA-G expression on the LCL721.221.G cells (14).
The three NK lines, NKG1, NKG2, and NKG7 are
strongly inhibited by HLA-G (Fig. 4). This inhibition is
mediated by the NKAT3 receptor (Figs. 5 a and 6). The
human KIR family interacts with the HLA class I mole-
cules via the a1 domain of the MHC class I heavy chain,
and especially by the three COOH-terminal turns of the
a helix belonging to this domain (40). The correct three-
dimensional folding of the HLA class I heavy chain for in-
teraction with the KIRs seems to be dependent on peptides
present in the binding groove (41, 42). However, direct in-
teraction of the inhibitory NK receptors with peptides
seems to be unlikely, because stabilization of empty HLA-C
molecules at 268C leads to the same level of inhibition as
endogenous peptide-loaded MHC class I molecules (33).
NK recognition of HLA class I molecules is especially sen-
sitive to the identity of the amino acids at positions 77 and
80 (Table 1). Resistance against NKAT1-bearing clones
could be transferred to HLA-C molecules normally recog-
nized by NKAT2 by changing S77 to N77 and N80 to
K80 (9). Protection against NKAT1-bearing NK clones, as
well as NKAT2-bearing NK clones, was abolished upon
mutation of position 80 (9, 33). Furthermore, NKAT3 rec-
ognizes HLA-Bw4 molecules with isoleucine or threonine
at position 80 with high statistical significance (40, 43) and
the NKAT4 receptor interacts with HLA-A3 (34, 44). On
comparing the primary structure of HLA-G to HLA-A, -B,
and -C sequences, a high homology for HLA-A2 can be
found (45). There is 89.9% similarity and 81.1% identity in
an amino acid sequence alignment. HLA-G also assembles
with b2m and the bound peptides show a distinct motif simi-
lar to classical MHC class I peptide motifs (14, 15). The
three-dimensional structure of HLA-G therefore is proba-
bly quite similar to the structure of classical HLA class I
molecules and it can be assumed that HLA-G interacts via
the same region with the inhibitory NK receptors as the
HLA-A, -B, and -C molecules. Comparison of the amino
acid sequence of HLA-G at positions 77–80 shows a clear
homology to HLA-Bw4 molecules in this particular region
(Table 1). At positions 77 and 80 in particular, HLA-Bw4
molecules possess distinct amino acids: position 77 is always
occupied either by asparagine, N; aspartic acid, D; or serin, S;
whereas position 80 is always threonine, T; or isoleucine, I.
In the HLA-G molecule, position 77 is occupied by aspar-
agine, N, and position 80 by threonine, T. This probably390 NK Inhibition by HLA-G
enables the NKAT3 receptor to interact with this region
and to mediate a negative signal to its NK cells, which pre-
vents target cell lysis.
In conclusion, we have demonstrated that NK inhibition
by HLA-G is, in part at least, mediated by the NKAT3 re-
ceptor. The inhibition of NK-mediated cell lysis is proba-
bly essential for the survival of the fetal semiallograft in the
mother during pregnancy. Thus, deletion of HLA-G or mu-
tations in this gene might lead to loss of the fetus in early
pregnancy.
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